8UAC

CATHEPSIN L IN COMPLEX WITH AC1115

Summary for 8UAC

• Entry DOI: 10.2210/pdb8uac/pdb
• Descriptor: Cathepsin L, N-[(2S)-1-({(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-1H-indole-2-carboxamide (3 entities in total)
• Functional Keywords: viral entry, cysteine protease, protein catabolism, inflammation, covid-19, hydrolase, hydrolase-inhibitor complex, hydrolase/inhibitor
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 2
• Total formula weight: 49212.40

Authors

Chao, A.,DuPrez, K.T.,Han, F.Q. (deposition date: 2023-09-20, release date: 2024-02-07, Last modification date: 2024-08-21)

Primary citation

Mao, L.,Shaabani, N.,Zhang, X.,Jin, C.,Xu, W.,Argent, C.,Kushnareva, Y.,Powers, C.,Stegman, K.,Liu, J.,Xie, H.,Xu, C.,Bao, Y.,Xu, L.,Zhang, Y.,Yang, H.,Qian, S.,Hu, Y.,Shao, J.,Zhang, C.,Li, T.,Li, Y.,Liu, N.,Lin, Z.,Wang, S.,Wang, C.,Shen, W.,Lin, Y.,Shu, D.,Zhu, Z.,Kotoi, O.,Kerwin, L.,Han, Q.,Chumakova, L.,Teijaro, J.,Royal, M.,Brunswick, M.,Allen, R.,Ji, H.,Lu, H.,Xu, X.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 M pro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Med, 5:42-61.e23, 2024

PubMed Abstract: Oral antiviral drugs with improved antiviral potency and safety are needed to address current challenges in clinical practice for treatment of COVID-19, including the risks of rebound, drug-drug interactions, and emerging resistance.

PubMed: 38181791
DOI: 10.1016/j.medj.2023.12.004

Experimental method

X-RAY DIFFRACTION (1.4 Å)